Risk for infection(s) from fiducial marker placement

Most of us who have gone through any form of image-guided external beam radiotherapy have had TRUS-guided transrectal placement of gold fiducial markers or radio transponders placed in our prostates. Some who have had salvage radiation have had them placed in the prostate bed. … READ MORE …

Can the “bone scan index” act as a surrogate marker for survival?

One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …

Risks associated with implantation of “fiducial markers” before radiation therapy

It is becoming commonplace for men who are going to get external beam radiotherapy to treat their prostate cancer to have some form of “fiducial marker” (often tiny gold rods or balls) inserted into their prostates under transrectal ultrasound guidance to help ensure that the radiotherapy can be administered with the greatest possible accuracy. … READ MORE …

Who needs aggressive treatment after initial radiation … and who does not?

A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality. … READ MORE …

Prostasomes — another possible marker for prostate cancer aggression?

A story in Science Daily, based on new article in the Proceedings of the National Academy of Sciences (PNAS) , has suggested that blood levels of “prostasomes” may be a more accurate marker for prostate cancer risk that PSA levels in blood. … READ MORE …

Inflammation, biomarkers, and risk for prostate cancer

Whether there is any real association (let alone a cause and effect correlation) between clinically evident or subclinical inflammatory disorders and risk for prostate cancer is still not known — although long suspected. … READ MORE …

Is free, circulating DNA a useful marker for prostate cancer?

Elevated levels of free, circulating DNA (fcDNA) have previously been been found in the serum of prostate cancer patients compared with the levels in the serum of patients with benign prostate conditions. … READ MORE …